The most important issue facing the biotechnology industry last year - and again in the coming year - is legislation governing follow-on biologics, said Nick Littlefield, partner and chairman of the government strategies group at the Boston law firm Foley Hoag LLP. (BioWorld Today)
The most important issue facing the biotechnology industry last year - and again in the coming year - is legislation governing follow-on biologics, said Nick Littlefield, partner and chairman of the government strategies group at the Boston law firm Foley Hoag LLP. (BioWorld Today)
Rather than drafting a separate proposal about approval authority for follow-on biologics, the FDA has agreed to work with lawmakers on developing that legislation. (BioWorld Today)
Rather than drafting a separate proposal about approval authority for follow-on biologics, the FDA has agreed to work with lawmakers on developing that legislation. (BioWorld Today)
